600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.
Noon Closed 08-06 11:29:59
52.73
-0.81
-1.51%
High53.81Low52.58Vol51.18M
Open53.65D1 Closing53.54Amplitude2.30%
Mkt Cap349.97BTradable Cap336.36BTotal Shares6.64B
T/O2.71BT/O Rate0.80%Tradable Shares6.38B
P/B5.59ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

HENGRUI PHARMA's Zhang Lianshan: Global Strategy at a Turning Point, Innovative Drug Firms Must Ultimately Go Global Independently
Deep News  ·  10:00
HENGRUI PHARMA's Zhang Lianshan: Global Strategy at a Turning Point, Innovative Drug Firms Must Ultimately Go Global Independently
Hengrui Pharma Completes 13.75 Million Share Buyback as of July 31
Stock News  ·  08-04 18:12
Hengrui Pharma Completes 13.75 Million Share Buyback as of July 31
HENGRUI PHARMA's Subsidiary Secures Approval for Clinical Trial Initiation
Stock News  ·  08-04 17:42
HENGRUI PHARMA's Subsidiary Secures Approval for Clinical Trial Initiation
Jiangsu Hengrui Files HKEX Next-Day Disclosure Return Reporting Share Repurchase at RMB 52.96
Reuters  ·  08-03 16:47
Jiangsu Hengrui Files HKEX Next-Day Disclosure Return Reporting Share Repurchase at RMB 52.96
Metis TechBio Jumps on Jiangsu Hengrui-tie up on AI Formulation Platform
Reuters  ·  08-03 13:48
Metis TechBio Jumps on Jiangsu Hengrui-tie up on AI Formulation Platform
METIS TECHBIO-P Deploys AI Drug Formulation Platform at HENGRUI PHARMA, Accelerating NanoForge Commercialization
Stock News  ·  08-03
METIS TECHBIO-P Deploys AI Drug Formulation Platform at HENGRUI PHARMA, Accelerating NanoForge Commercialization
Metis Techbio Co - Announces Aitem AI Platform Deployment at Jiangsu Hengrui Pharmaceuticals
THOMSON REUTERS  ·  08-03
Metis Techbio Co - Announces Aitem AI Platform Deployment at Jiangsu Hengrui Pharmaceuticals
The Capital Group Companies Increases Stake in Hengrui Pharma with 483,600 Share Purchase at Approximately HK$57.90 Each
Deep News  ·  08-03
The Capital Group Companies Increases Stake in Hengrui Pharma with 483,600 Share Purchase at Approximately HK$57.90 Each
Hengrui Pharma Wins China Regulator's Nod for Three Drugs
MT Newswires Live  ·  07-30
Hengrui Pharma Wins China Regulator's Nod for Three Drugs
Capital Group Boosts Stake in Hengrui Pharma with 752,200 Share Purchase
Deep News  ·  07-30
Capital Group Boosts Stake in Hengrui Pharma with 752,200 Share Purchase
Hengrui Pharma's Self-Developed Class 1 Biologic Insulin Analogue Receives Market Approval
Stock News  ·  07-29
Hengrui Pharma's Self-Developed Class 1 Biologic Insulin Analogue Receives Market Approval
Jiangsu Hengrui Receives Approval for China's First Self-Developed Long-Acting Insulin Analog
Stock News  ·  07-29
Jiangsu Hengrui Receives Approval for China's First Self-Developed Long-Acting Insulin Analog
Market Highlights: First Domestically Developed Long-Acting Diabetes Treatment Approved, Hengrui Pharma Leads
Stock News  ·  07-29
Market Highlights: First Domestically Developed Long-Acting Diabetes Treatment Approved, Hengrui Pharma Leads
Hengrui Pharmaceuticals Says Shudi Insulin Injection Approved by NMPA
Reuters  ·  07-29
Hengrui Pharmaceuticals Says Shudi Insulin Injection Approved by NMPA
Jiangsu Hengrui Pharmaceuticals Says Self-Developed Class 1 Biologic Shudi Insulin Injection Approved for Market by China's Nmpa
THOMSON REUTERS  ·  07-29
Jiangsu Hengrui Pharmaceuticals Says Self-Developed Class 1 Biologic Shudi Insulin Injection Approved for Market by China's Nmpa
Hengrui Pharma's Recombinant Anti-Tumor Antibody Injection Receives NMPA Approval Application Submission
Stock News  ·  07-29
Hengrui Pharma's Recombinant Anti-Tumor Antibody Injection Receives NMPA Approval Application Submission
Jiangsu Hengrui Pharmaceuticals Says Its Shr-4375 Injection for Pancreatic Cancer Granted Orphan Drug Designation by U.S. FDA
THOMSON REUTERS  ·  07-27
Jiangsu Hengrui Pharmaceuticals Says Its Shr-4375 Injection for Pancreatic Cancer Granted Orphan Drug Designation by U.S. FDA
Citigroup’s Short Position in H-shares of Jiangsu Hengrui Pharmaceuticals Decreases to 2.53% on July 20 from 3.07% - HKEX Filing
THOMSON REUTERS  ·  07-24
Citigroup’s Short Position in H-shares of Jiangsu Hengrui Pharmaceuticals Decreases to 2.53% on July 20 from 3.07% - HKEX Filing
Hengrui Pharma Wins China Approval for Camrelizumab-famitinib Combo as 1L Cervical Cancer Treatment
Reuters  ·  07-23
Hengrui Pharma Wins China Approval for Camrelizumab-famitinib Combo as 1L Cervical Cancer Treatment
Jiangsu Hengrui Pharmaceuticals, Unit Receive Chinese Regulator's Approval for Innovative Drug
Reuters  ·  07-23
Jiangsu Hengrui Pharmaceuticals, Unit Receive Chinese Regulator's Approval for Innovative Drug

Introduction

Company Name.
江苏恒瑞医药股份有限公司
Industry:
医药制造业
Listing Date:
2000-10-18
Main Business:
　　江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。
Issue price:
11.98